Initiation of venovenous extracorporeal membrane oxygenation in a patient receiving induction chemotherapy for acute myelogenous leukemia

Abstract

Background

Acute respiratory failure is a leading cause of intensive care unit admission in patients with hematological malignancies; it carries a mortality rate exceeding 50%. Venovenous extracorporeal membrane oxygenation use in patients with acute hematologic malignancies concurrently receiving induction chemotherapy is not well studied.

Case presentation

A 44-year-old male developed acute respiratory distress syndrome in the setting of newly diagnosed acute myelogenous leukemia. He underwent successful induction chemotherapy while on venovenous extracorporeal membrane oxygenation. His course was complicated by a devastating subarachnoid hemorrhage. Life support modalities were discontinued in accordance to the wishes of the family.

Conclusion

There is a lack of data to guide use of induction chemotherapy in patients with acute hematologic malignancies requiring venovenous extracorporeal membrane oxygenation, particularly with regard to dosing, safety, and efficacy of chemotherapeutic agents. This case highlights a potential role of venovenous extracorporeal membrane oxygenation in select young acute myelogenous leukemia patients who might benefit from this intervention and warrants further research.

Keywords

Acute myelogenous leukemia acute respiratory distress syndrome extracorporeal membrane oxygenation induction chemotherapy

Get full access to this article

View all access options for this article.

References

Stone

O'Donnell

Sekeres

. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004, pp. 98–117.

Sekeres MA. Acute Myeloid Leukemia, http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/ (2017, accessed 27 September 2017).

Rabe

Mey

Paashaus

et al.

Outcome of patients with acute myeloid leukemia and pulmonary infiltrates requiring invasive mechanical ventilation-a retrospective analysis. J Crit Care 2004; 19: 29–35.

Bellani

Laffey

Pham

et al.

Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788–800.

Kraguljac

Croucher

Christian

et al.

Outcomes and predictors of mortality for patients with acute leukemia admitted to the intensive care unit. Can Respir J 2016; 2016: 3027656.

Roze des Ordons

Chan

Mirza

et al.

Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study. BMC Cancer 2010; 10: 516.

Wohlfarth

Ullrich

Staudinger

et al.

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. Crit Care 2014; 18: R20.

Lee

Kim

Hong

. Extracorporeal membrane oxygenation as a rescue therapy for acute respiratory failure during chemotherapy in a patient with acute myeloid leukemia. J Thorac Dis 2017; 9: E133–E137.

Lueck

Kuehn

Hoeper

et al.

Successful use of extracorporeal membrane oxygenation during induction chemotherapy in a patient with mediastinal tumor mass of a T lymphoblastic lymphoma. Ann Hematol 2016; 95: 1719–1721.

10.

Health NIo. Cancer Stat Facts: Acute Myeloid Leukemia (AML), https://seer.cancer.gov/statfacts/html/amyl.html (accessed 05 October 2017).

11.

Vadde R and Pastores SM. Management of acute respiratory failure in patients with hematological malignancy. J Intensive Care Med 2015; 31: 627–641.

12.

Huang

Owen

Myers

et al.

Cardiopulmonary failure requiring ECMO bypass resulting from leukemia cell lysis in a patient with childhood acute myelomonocytic leukemia. Case Rep Hematol 2015; 2015: 640528.

13.

Moreau

Lengline

Seguin

et al.

Respiratory events at the earliest phase of acute myeloid leukemia. Leuk Lymphoma 2014; 55: 2556–2563.

14.

Zapol

Snider

Hill

et al.

Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 1979; 242: 2193–2196.

15.

Maslach-Hubbard

Bratton

. Extracorporeal membrane oxygenation for pediatric respiratory failure: history, development and current status. World J Crit Care Med 2013; 2: 29–39.

16.

Kulkarni

Sharma

Diaz-Guzman

. Extracorporeal membrane oxygenation in adults: A practical guide for internists. Cleve Clin J Med 2016; 83: 373–384.

17.

Sharma

Wille

Bellot

et al.

Modern use of extracorporeal life support in pregnancy and postpartum. ASAIO J 2015; 61: 110–114.

18.

Ried

Bein

Philipp

et al.

Extracorporeal lung support in trauma patients with severe chest injury and acute lung failure: a 10-year institutional experience. Crit Care 2013; 17: R110.

19.

Gow

Lao

Leong

et al.

Extracorporeal life support for adults with malignancy and respiratory or cardiac failure: the extracorporeal life support experience. Am J Surg 2010; 199: 669–675.

20.

Gattinoni

. Ultra-protective ventilation and hypoxemia. Crit Care 2016; 20: 130.

21.

Schmidt

Bailey

Sheldrake

et al.

Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med 2014; 189: 1374–1382.

22.

Aokage

Palmer

Ichiba

et al.

Extracorporeal membrane oxygenation for acute respiratory distress syndrome. J Intensive Care 2015; 3: 17.

23.

Amini

Peiman

Khatuni

et al.

The effect of dextromethorphan premedication on cough and patient tolerance during flexible bronchoscopy: a randomized, double-blind, placebo-controlled trial. J Bronchology Interv Pulmonol 2017; 24: 263–267.

24.

Shekar

Roberts

McDonald

et al.

Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care 2015; 19: 164.

25.

Cytarabine [Package Insert]. New York, NY 2011.

26.

Idarubicin [Package Insert]. New York, NY 2006.

27.

Koren

Beatty

Seto

et al.

The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992; 26: 363–371.

28.

Perry M. The Chemotherapy Source Book, 5th ed. Lippincott Williams & Wilkins. Philadelphia, PA 2008.

29.

Radeski

Cull

Cain

et al.

Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. Cancer Chemother Pharmacol 2011; 67: 765–768.

30.

Aronoff GR BW and Berns JS. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 22: American College of Physicians. Philadelphia, PA 2007.

31.

Tapper

Luptakova

Joyce

et al.

A 78-year-old man with acute myeloid leukemia (AML) and acute renal failure. Am J Case Rep 2014; 15: 364–367.

32.

Dillman

Davis

Green

et al.

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78: 2520–2526.

33.

Fernandez

Sun

Yao

et al.

Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249–1259.

34.

Wiernik

Banks

Case

Jr et al.

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319.

35.

Lee

Kim

Joo

et al.

Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol 2017; 35: 2754–2763.